Rigaku Launches Fourth Generation Handheld 1064 nm Raman Analyzer for Chemical Threat Analysis at IAFC HAZMAT 2025
The Icon-X is the first 1064 nm Raman analyzer to provide standoff chemical analysis allowing users to analyze potentially dangerous substances from a safe distance. This is critical for military, first responders, EOD, and border protection teams who could potentially be exposed to explosive threats, such as improvised explosive devices (IEDs), homemade explosives (HMEs), and chemical threats. This new, optional feature also reduces the need for time-consuming sample collection, while allowing responders to assess hazards without disrupting the scene.
In addition to the new standoff capability, the Icon-X contains an on-board, comprehensive library of chemical warfare agents (CWAs), explosives, narcotics, toxic industrial chemicals, precursors, cutting agents, and more. The Icon-X features a more ergonomic form factor, with improvements in all areas over previous generations, including:
Use of the latest technology for enhanced processing
Illuminated keypad and larger, more responsive touchscreen for easier use
Optional GPS ability to mark critical scan data for fleet management and sensitive site exploitation
Upgraded 13MP camera with LED flash for more clear images
Meets the MIL-STD-810H standard for durability, passing tests for shock, pressure, and extreme temperatures. It also has IP68 certification, making it fully dustproof and waterproof—ideal for tough environments and decontamination use
New accessories to expand applications, such as a ball probe to scan inside a deep container
As criminal networks become more sophisticated with easier access to chemicals and dangerous recipes, the need for first responders to have cutting-edge technology has never been more critical. Based on the success of Rigaku's previous generations of handheld 1064 nm Raman technology, the Icon series provides users with reliable results, allowing them to respond faster, while keeping them safe from exposure. The utilization of 1064 nm Raman technology means users can scan through translucent packaging and identify dirty or mixed substances without fluorescence issues, a common issue for older Raman technology.
'While developing the Icon Series, we considered the years of feedback received from our global network of 1064 nm Raman users and partners,' said Dr. Michael Hargreaves, Vice President of Science & Technology at Rigaku Analytical Devices. 'This allowed us to take a proven, field-accessible technology to the next level, and really expand the capabilities of handheld Raman spectroscopy. '
The Rigaku Icon-X will be demonstrated in booth #314 at the IAFC Hazmat Show in Baltimore, MD USA from June 13-14, 2025.
The Rigaku Icon-X joins the award-winning 1064 nm fleet of Rigaku CQL analyzers and is supported by Rigaku's global sales and distribution channels. For more information on the Icon-X, please visit: www.rigakuanalytical.com.
About the Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations 'To Improve Our World by Powering New Perspectives.'
For details, please visit rigaku-holdings.com/english
About Rigaku Analytical Devices
Rigaku Analytical Devices is a pioneer in handheld 1064 nm Raman spectroscopy. Our products are trusted by law enforcement departments, government agencies, and security specialists to identify chemical threats. The pharmaceutical manufacturing sector relies on us for quality control. At Rigaku, we are focused on supporting our clients with our global expertise and developing innovative solutions that perform optimally, mitigate new chemical threats, and are always reliable and cost effective. Our rugged products deliver unparalleled accuracy and support for rapid lab-quality results any time, any place. For more information: http://www.rigakuanalytical.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
SRPT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sarepta's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Sarepta class action lawsuit, please provide your information here: CASE ALLEGATIONS: Sarepta is a commercial-stage biopharmaceutical company. According to the complaint, during the Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ('Duchenne'), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; and (iii) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals. The Sarepta class action lawsuit further alleges that on March 18, 2025, Sarepta revealed that a patient treated with ELEVIDYS suffered acute liver failure leading to death, which represented 'a severity of acute liver injury not previously reported for ELEVIDYS.' On this news, the price of Sarepta stock fell more than 27%, according to the complaint. Then, on April 4, 2025, the Sarepta class action lawsuit further alleges that Sarepta disclosed that European Union member country authorities had requested that the independent data monitoring committee meet to review the death announced on March 18, 2025, resulting in Sarepta halting recruitment and dosing in some of the ELEVIDYS clinical studies. On this news, the price of Sarepta stock fell more than 7%, according to the complaint. Thereafter, on June 15, 2025, Sarepta disclosed that a second patient had died of acute liver failure following treatment with ELEVIDYS, leading to Sarepta suspending shipment of ELEVIDYS for non-ambulatory patients and pausing dosing of ELEVIDYS in the ENVISION clinical study to evaluate the protocol in accordance with the U.S. Food and Drug Administration ('FDA'), according to the complaint. The Sarepta class action lawsuit alleges that on this news, the price of Sarepta stock fell more than 42%. Finally, the Sarepta class action lawsuit further alleges that on June 24, 2025, the FDA issued a Safety Communication announcing it had received reports of two deaths and was investigating the risk of acute liver failure with serious outcomes following treatment with ELEVIDYS. On this news, the price of Sarepta stock fell more than 8%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Sarepta securities during the Class Period to seek appointment as lead plaintiff in the Sarepta class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Sarepta class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Sarepta class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Sarepta class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Business Wire
an hour ago
- Business Wire
Cintas Corporation Announces Webcast for Fourth Quarter Fiscal Year 2025 Results
CINCINNATI--(BUSINESS WIRE)--Cintas Corporation (Nasdaq: CTAS) today announced that it will release fiscal year 2025 fourth quarter and full year results on Thursday, July 17, 2025. The Company will conduct a conference call to address the financial results. A live webcast of the call will be available to individual investors and the public beginning at 10:00 a.m., Eastern Time, on Thursday, July 17, 2025. The webcast will be available at Click on the webcast icon and then follow instructions. For those unable to listen to the live webcast, a replay will be available on the Company's website beginning approximately two hours after the completion of the live call and will remain available for two weeks. About Cintas Corporation Cintas Corporation helps more than one million businesses of all types and sizes get Ready™ to open their doors with confidence every day by providing products and services that help keep their customers' facilities and employees clean, safe, and looking their best. With offerings including uniforms, mats, mops, towels, restroom supplies, workplace water services, first aid and safety products, eye-wash stations, safety training, fire extinguishers, sprinkler systems and alarm service, Cintas helps customers get Ready for the Workday®. Headquartered in Cincinnati, Cintas is a publicly held Fortune 500 company traded over the Nasdaq Global Select Market under the symbol CTAS and is a component of both the Standard & Poor's 500 Index and Nasdaq-100 Index.
Yahoo
an hour ago
- Yahoo
UiPath Names Romanian Olympic Swimming Champion David Popovici as Global Ambassador
Four-year partnership deal will support the athlete's Olympic journey and quest for swimming excellence NEW YORK, July 03, 2025--(BUSINESS WIRE)--UiPath (NYSE: PATH), a global leader in agentic automation, today announced that it has named Romanian Olympic swimming champion David Popovici a Global Ambassador. In this capacity, Popovici will be attending and speaking at several UiPath events globally. The partnership, spanning four years, will support the young athlete throughout his preparation for the biggest European and world swimming competitions, culminating with the 2028 Summer Olympic Games in Los Angeles. A freestyle swimming specialist, the 20-year-old Bucharest-born David Popovici broke into the elite swimming scene with a standout performance at the 2022 World Championships. Then aged 17, Popovici became the first male swimmer in 49 years to win the 100m and 200m freestyle at the same World Championships. He also became the second-youngest swimmer ever to win the men's 200m world title. Popovici went on to win gold in the 200m and the 100m freestyle at the 2022 European Championships, becoming the second-youngest male swimmer ever to break the 100m freestyle world record, while also setting a new world junior record in the 200m race. In 2024, Popovici went on to improve on a fourth-place ranking in the 200m freestyle race at the 2021 Tokyo Olympics by winning the gold medal at the Paris 2024 Olympic Games in the same race. He also won a bronze medal in the men's 100m freestyle final. Currently, Popovici is training towards his third consecutive Olympic Games and will next compete in the Singapore 2025 World Aquatics Championships. "What makes David a champion isn't just raw talent – it's his ability to bring together every element that drives excellence: discipline, mindset, training, recovery, and the will to do it all over again. That kind of integration is what unlocks true performance. I see a similar principle in how we think about the future of technology: real breakthroughs happen when you combine the right parts – people, technology, and intelligence – into something greater than the sum of its parts. At UiPath, while we're shaping what technology can do, we're just as focused on the humans behind it. Our vision of agentic orchestration is about uniting people, AI agents, models, and robots into a cohesive system – just like David brings together every part of his craft. He's the perfect embodiment of the harmony between precision, perseverance, and purpose," said UiPath Co-Founder and CEO Daniel Dines. "I am delighted to share my journey with a partner who genuinely understands what it takes to excel in one's field. As a sportsman, I know firsthand that achieving global success requires hard work, discipline, unwavering motivation and the belief that you can win every time. UiPath is a place where innovative ideas are supported, where everyone is encouraged to express their creativity and contribute to developing the best technology in the world. It feels natural to partner with UiPath, a strong brand with a global impact that has remained true to its roots. We share much of the same journey, and this partnership goes beyond support – it's built on trust and shared values, representing a big source of inspiration to me," said Olympic champion David Popovici. Between September 29 – October 1, 2025, UiPath will hold the first edition of UiPath FUSION, a high-touch, high-tech, white-glove event for the most passionate and innovative members of the UiPath ecosystem. David Popovici will join UiPath Co-Founder and CEO Daniel Dines on stage during the event. Register here to join UiPath FUSION at the Wynn Las Vegas. About UiPath UiPath (NYSE: PATH) is a global leader in agentic automation, empowering enterprises to harness the full potential of AI agents to autonomously execute and optimize complex business processes. The UiPath Platform™ uniquely combines controlled agency, developer flexibility, and seamless integration to help organizations scale agentic automation safely and confidently. Committed to security, governance, and interoperability, UiPath supports enterprises as they transition into a future where automation delivers on the full potential of AI to transform industries. For more information, visit View source version on Contacts Media ContactUiPathpr@ Investor Relations Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
